Wikipedia -WSS

Wikipedia

author：fashion 2025-09-02 22:26:38 - browse：44

An AstraZeneca sign at ESMO in Madrid. — An AstraZeneca ad at ESMO 2023 in Madrid. Andrew Joseph/STAT

MADRID — Questions about one of AstraZeneca’s key cancer drug candidates — and the dribs and drabs that have come out about its performance — have been dogging the company for months.

On Monday, data presented here from a trial of the drug in advanced non-small cell lung cancer provided at least a fuller look. While the results assuaged some of the safety fears that flared when initial information was released over the summer, they only heightened concerns about the drug’s ability to outperform standard chemotherapy — though they perhaps pointed to an opportunity for the drug in a subset of patients.

The trial, detailed here in a prime session at the annual meeting of the European Society for Medical Oncology, is testing a therapy called datopotamab deruxtecan, or Dato-DXd, in advanced or metastatic non-small cell lung cancer in patients who already tried at least first-line treatments. Patients were randomized to either receive chemotherapy or Dato-DXd, which AstraZeneca is developing with Daiichi Sankyo.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： Food makers to regulators: Ultra

WSS

Maisha Meds is a PBM, but don't call it that

High breast density mammograms need follow

Inaction leaves children at risk from dangerous chemotherapy drug

Medicare bonuses could stop drug shortages under Senate plan

Cardiologists urge adding sexual orientation, gender identity to health records

New weight loss drugs vying to be the next Wegovy or Mounjaro

leisure time

Wikipedia

focus

What does generative AI mean for health care? We asked experts

Future doctors need a strong humanities education

Activists slam private health insurers over coverage restrictions

Head of FDA's diagnostics center, who led through Covid, retires

Hollywood unions extend contract negotiations for actors

Sanofi to acquire U.S. biotech Inhibrx in $2.2 billion deal

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Popular nasal decongestant doesn't actually relieve congestion

Supreme Court strikes down use of affirmative action

IRA could hurt research into orphan drugs for rare diseases

leisure time

Readout Newsletter: Parkinson's study, Gilead, CG Oncology

How to make the FDA’s new prescription one

To bolster infectious disease surveillance, genomics powerhouses team up

Long Covid needs a new name — and a new frame

Inaction leaves children at risk from dangerous chemotherapy drug

Listen: Covid's latest surge, Alnylam at the FDA, & the end of an era

hotspot

focus

focus

hotspot